Compare KRRO & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | SANG |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.0M | 157.1M |
| IPO Year | 2019 | 2018 |
| Metric | KRRO | SANG |
|---|---|---|
| Price | $11.80 | $4.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 4 |
| Target Price | ★ $20.20 | $5.50 |
| AVG Volume (30 Days) | 168.2K | ★ 306.6K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,392,000.00 | N/A |
| Revenue This Year | N/A | $3.23 |
| Revenue Next Year | $56.67 | $0.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 181.46 | N/A |
| 52 Week Low | $5.20 | $3.40 |
| 52 Week High | $42.70 | $5.42 |
| Indicator | KRRO | SANG |
|---|---|---|
| Relative Strength Index (RSI) | 60.96 | 56.23 |
| Support Level | $10.18 | $4.64 |
| Resistance Level | $14.50 | $4.66 |
| Average True Range (ATR) | 0.99 | 0.09 |
| MACD | 0.41 | -0.05 |
| Stochastic Oscillator | 85.66 | 0.00 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic location USA and Other countries. Key revenue is generated from USA.